Neil Agrawal, MD
Cardiovascular Disease · Tulsa, OKNPI 1902935729
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (58.2%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Heartflow, Inc. accounts for 76.4% of it on its own, with 28 other manufacturers making up the rest. 2025 is the largest year on record at $6,391, more than ten times the $249 reported in 2019.
Across 159 payments — averaging $64.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Heartflow, Inc.$8K
- Novo Nordisk$298
- Abiomed$267
- AstraZeneca$208
- Boehringer Ingelheim$193
- E.r. Squibb & Sons, L.L.C.$167
- plus $1K from 23 others
What the payments were for
- Consulting fees$6,00058%
- Travel & lodging$7427%
- Food & beverage$3,45334%
- Education$1091%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Heartflow, Inc. | 29 | $7,874 |
| Novo Nordisk | 14 | $298 |
| Abiomed | 6 | $267 |
| AstraZeneca | 10 | $208 |
| Boehringer Ingelheim | 11 | $193 |
| E.r. Squibb & Sons, L.L.C. | 10 | $167 |
| Merck | 8 | $132 |
| Johnson & Johnson | 8 | $124 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 10 | $117 |
| Amgen | 7 | $115 |
| Boston Scientific | 6 | $107 |
| Pfizer | 6 | $97 |
| Novartis | 5 | $86 |
| Esperion Therapeutics, Inc. | 4 | $76 |
| GE HealthCare | 2 | $67 |
| Alnylam Pharmaceuticals Inc. | 4 | $66 |
| Philips North America LLC | 3 | $54 |
| Edwards Lifesciences | 3 | $49 |
| Abbott | 2 | $42 |
| Lexicon Pharmaceuticals, Inc. | 2 | $29 |
| Smith+Nephew | 1 | $20 |
| Baxter Healthcare | 1 | $20 |
| Medtronic | 1 | $16 |
| Angiodynamics, Inc. | 1 | $16 |
| Sanofi-aventis U.S. LLC | 1 | $15 |
| Chiesi USA, Inc. | 1 | $14 |
| Irhythm Technologies, Inc. | 1 | $13 |
| Regeneron Healthcare Solutions, Inc. | 1 | $12 |
| Astellas Pharma US Inc | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,305 in reported general payments places this provider in the 85th percentile of 164 cardiovascular disease providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 167 | $179,660 |
| JardianceEmpagliflozin | 122 | $129,241 |
| OzempicSemaglutide | 69 | $70,194 |
| XareltoRivaroxaban | 34 | $43,652 |
| EntrestoSacubitril/Valsartan | 23 | $41,383 |
| Repatha SureclickEvolocumab | 49 | $30,802 |
| WegovySemaglutide | 19 | $25,087 |
| FarxigaDapagliflozin Propanediol | 23 | $17,481 |
| Atorvastatin Calcium | 346 | $8,854 |
| Rosuvastatin Calcium | 109 | $3,870 |
| Ezetimibe | 107 | $3,593 |
| Metoprolol Tartrate | 178 | $2,229 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 82 | $1,359 |
| Ranolazine ErRanolazine | 15 | $1,216 |
| Amlodipine Besylate | 96 | $918 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $97 | $179,660167 claims |
| Boehringer IngelheimJardiance | $193 | $129,241122 claims |
| Novo NordiskOzempic, Wegovy | $298 | $95,28188 claims |
| Johnson & JohnsonXarelto | $124 | $43,65234 claims |
| NovartisEntresto | $86 | $41,38323 claims |
| AstraZenecaFarxiga | $208 | $17,48123 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 164 cardiovascular disease providers in Oklahoma.
Other cardiovascular disease in Tulsa
- Frank GaffneyTulsa$211K
- Mohamad KhattabTulsa$47K
- Steve KimTulsa$38K
- Eric AuerbachTulsa$35K
- David WilkettTulsa$25K
- Daniel WildesTulsa$24K
- Thomas KalapuraTulsa$17K
- Heather ChaTulsa$16K
- Christopher HigginsTulsa$13K
- Alan KaneshigeTulsa$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.